Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia.

about

Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia.

Item

http://www.wikidata.org/entity/Q40817438

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Challenges for the next decade ...... chronic lymphocytic leukemia.

@en

type

Item

label

Challenges for the next decade ...... chronic lymphocytic leukemia.

@en

prefLabel

Challenges for the next decade ...... chronic lymphocytic leukemia.

@en

P1476

Challenges for the next decade ...... chronic lymphocytic leukemia.

@en

P2093

L Farina

http://www.w3.org/2001/XMLSchema#string

P Corradini

http://www.w3.org/2001/XMLSchema#string

P2860

High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.

Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901

Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies.

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.

Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.

Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.

P2888

leusup.2012.19

P304

S33-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEUSUP.2012.19

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047162248

http://www.w3.org/2001/XMLSchema#string

P698

27175243

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

P932

4851200

http://www.w3.org/2001/XMLSchema#string